Abbott Laboratories (ABT) is a diversified global healthcare company spanning medical devices, diagnostics, nutrition, and established pharmaceuticals. Reviewing individual price targets attributed to specific firms and analysts, the range runs from about $140 (Mizuho's Neutral view) up to $162 (Barclays), with most targets clustered between roughly $142 and $154. Recent individual figures include RBC Capital at $147, Bernstein at $154 (raised from $150), Jefferies at $149, BTIG at $145, Wells Fargo at $146, Raymond James at $146, Piper Sandler at $150, and UBS at $154.
The arithmetic mean of these targets is roughly $148.6, which rounds to a $150 central target. This figure is an independently calculated average, not an official published consensus, and independent trackers have at times reported a slightly lower consensus of about $144 to $147. The broad agreement among analysts is an Outperform-to-Buy stance, with the divergence concentrated in magnitude: more cautious analysts cite diagnostics pricing pressure and uneven growth, while more bullish analysts emphasize medical-device momentum and long-term earnings power. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The stock recently traded near $100.50, well below its 52-week range of roughly $105 to $141 after a sustained 2026 decline. Reaching $150 from that level implies upside of approximately 49%, which is a very large required move. Notably, most of the analyst targets that anchor the $150 mean were set when the stock traded materially higher, so the gap between the current price and the average target partly reflects the share-price decline rather than a fresh round of upgrades.
Fundamentally, ABT has delivered mid-to-high single-digit revenue growth and maintains a diversified revenue base that includes high-demand categories such as glucose monitoring and structural heart devices. However, the company recently lowered its full-year comparable sales growth outlook, citing weakness in electrophysiology and diabetes. A path toward the target would likely require a stabilization and re-acceleration in those businesses, margin recovery, and renewed investor confidence in the valuation.
Several factors could support a recovery. Abbott's medical-device segment, including its FreeStyle Libre continuous glucose monitoring platform and structural heart products, remains a durable growth engine with accelerating procedure volumes. The company's diversified model provides multiple revenue streams that can offset weakness in any single unit. A contemplated acquisition in the diagnostics and cancer-screening space is viewed by many analysts as strategically attractive over the long term, and Abbott's track record as an established dividend payer offers a measure of downside support. Analysts who remain constructive also point to a valuation that has compressed during the selloff and to double-digit earnings-growth potential if margins stabilize.
The principal obstacle is the company's own guidance. The reduction in full-year comparable sales growth, driven by electrophysiology and diabetes, raises questions about near-term execution and the consistency of growth outside medical devices. Margin compression is another concern, as operating margins have slipped year over year. Integration risk and the premium valuation associated with a potential acquisition could also limit multiple expansion, while hospital budget pressures and reimbursement dynamics create macro uncertainty. Several price-target trims in recent quarters, even while ratings stayed positive, signal that investors may already be discounting a meaningful portion of the long-term growth story, leaving less room for error.
After the 2026 decline, the stock sits near a multi-year support zone around the $100 area, with chart-based support observed near $95 and again near $89. On the upside, a notable resistance level appears around $128, where earlier rallies have stalled. That $128 area is itself well below the $150 central target, meaning the stock would first need to clear a series of intermediate resistance levels before approaching the analyst average. The long-term structure has weakened, with the stock below its prior highs and trading near the lower end of its recent range. From what I see, monitoring these levels closely helps frame the risk-reward setup.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts differ, and the targets referenced here were largely set before the most recent guidance revision. Investors should monitor upcoming earnings and guidance, particularly comparable sales growth in electrophysiology and diabetes, operating-margin trends, and any updates on the diagnostics acquisition. Analyst target revisions, hospital-procedure volume data, reimbursement decisions, and broader healthcare-sector sentiment will also matter. None of this provides a definitive forecast, but it frames the conditions under which the gap toward $150 could narrow or widen.
In my own analysis, I often turn to Tickeron's AI Daily Buy/Sell Signals to track momentum shifts in names like Abbott that have seen sharp reversals. The tool uses artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions and technical behavior. It helps spot evolving trends without manually reviewing every chart, which can be useful when evaluating whether conditions are aligning toward a higher price target or if near-term headwinds persist.
The $150 target represents the arithmetic mean of verified analyst price targets, not a guarantee or a prediction. With the stock near $100.50, the move required is roughly 49%, which is very large, and the average target may not fully reflect the company's recent guidance cut and the sharp 2026 share-price decline. The strongest supports are Abbott's diversified portfolio and medical-device franchise, while the principal obstacles are weakening electrophysiology and diabetes momentum, margin pressure, and potential acquisition-related risk. Analyst disagreement centers on the magnitude of upside rather than direction. Investors should watch upcoming guidance, segment-level growth, and analyst revisions to gauge whether conditions are improving toward the target or drifting further away.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ABT declined for three days, in 169 of 298 cases, the price declined further within the following month. The odds of a continued downward trend are 57%.
The 10-day RSI Indicator for ABT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 17 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABT as a result. In 39 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
The Moving Average Convergence Divergence Histogram (MACD) for ABT turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 30 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
ABT moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.
ABT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for ABT crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +5.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in 170 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 126 of 258 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.722) is normal, around the industry mean (4.142). P/E Ratio (35.461) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.253). Dividend Yield (0.023) settles around the average of (0.011) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of health care products
Industry MedicalNursingServices